Emerging strategies for the preservation of pancreatic beta-cell function in early type 2 diabetes

Clinical and Investigative Medicine

Volumn 37, Issue 6, 2014, Pages E414-E420

  Retnakaran, Ravi ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS, TYPE 2; HUMAN; METABOLISM; PANCREAS ISLET BETA CELL; PATHOLOGY;

DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN-SECRETING CELLS;

EID: 84939432361     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
2. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations:from pathophysiology to prevention and management. Lancet 2011; 378(9786): 169-181.
3. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009; 52(6): 1003-1012.
4. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diab Res Clin Pract 1998; 40 Suppl: S21-25.
5. Retnakaran R, Qi Y, Harris SB, Hanley AJ, Zinman B. Changes over time in glycemic control, insulin sensitivity, and beta-cell function in response to low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Care 2011; 34(7): 1601-1604.
6. Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: The LIBRA trial. Diabetes Care 2014; 37: 3270-3278.
7. Retnakaran R, Qi Y, Ye C, Hanley AJ, Connelly PW, Sermer M, Zinman B. Hepatic insulin resistance is an early determinant of declining beta-cell function in the first year postpartum following glucose intolerance in pregnancy. Diabetes Care 2011; 34(11): 2431-2434.
8. Kramer CK, Swaminathan B, Hanley AJ, Connelly PW, Sermer M, Zinman B, Retnakaran R. Each degree of glucose intolerance in pregnancy predicts distinct trajectories of beta-cell function, insulin sensitivity and glycemia in the first 3 years postpartum. Diabetes Care 2014, in press {Epub ahead of print Sept 17 2014}
9. Kato N. Insights into the genetic basis of type 2 diabetes. J Diabetes Investig 2013; 4(3):233-244
10. Turner RC, Cull CA, Frighi V, Holman RR for the UKPDS Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12.
11. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.
12. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. b-cell deficit and increased b-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
13. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic b-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008; 10 Suppl 4: 32-42.
14. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008; 29(3): 351-366.
15. Brunzell JD, Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42: 222-29.
16. Kashyap S, Belfort R, Gastaldelli A et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003; 52: 2461-2474.
17. Kramer CK, Choi H, Zinman B, Retnakaran R. Determinants of reversibility of beta-cell dysfunction in response to short-term intensive insulin therapy in early type 2 diabetes. Am J Physiol Endocrinol Metab 2013; 305(11):E1398-1407.
18. Retnakaran R, Zinman B. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on beta-cell function. Diabetes Obes Metab 2012; 14(Suppl 3):161-166.
19. Retnakaran R, Drucker DJ. Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet 2008; 371(9626): 1725-6.
20. Li Y, Xu W, Liao Z et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004; 27: 2597-2602.
21. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20: 1353-1356.
22. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27: 1028-1032.
23. Weng J, Li Y, Xu W et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicenter randomised parallelgroup trial. Lancet 2008; 371: 1753-1760.
24. Chen A, Huang Z, Wan X et al. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care 2012; 35(3): 474-481.
25. Park S, Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 2003; 19: 124-130.
26. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B. The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010; 12: 65-71.
27. Liu L, Wan X, Liu J, Huang Z, Cao X, Li Y. Increased 1,5-Anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. Diabetes Technology and Therapeutics 2012; 14(9): 1-6.
28. Xu W, Li YB, Deng WP, Hao YT, Weng JP. Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. Chin Med J (Engl) 2009; 122: 2554-9.
29. Hu Y, Li L, Xu Y et al. Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and β-cell function in subjects with long-term remission. Diabetes Care 2011; 34: 1848-1853.
30. Chen H, Ren A, Hu S, Mo W, Xin X, Jia W. The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Res Clin Pract 2007; 75: 327-332.
31. Zhao Q, Wang H, Sun C, Ma A, Cui C. Effect of short-term intensive treatment with insulin pump on beta cell function and the mechanism of oxidative stress in newly diagnosed type 2 diabetic patients. Nan Fang Yi Ke Da Xue Xue Bao 2007:27(12):1878-9.
32. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008; 31: 1927-1932.
33. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy and its impact on type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013; 1(1): 28-34.
34. Kramer CK, Choi H, Zinman B, Retnakaran R. Glycemic variability in patients with early type 2 diabetes: the impact of improvement in beta-cell function. Diabetes Care 2014; 37(4): 1116-1123.
35. Kramer CK, Vuksan V, Choi H, Zinman B, Retnakaran R. Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: Reproducibility and implications for glucose homeostasis in individuals with and without diabetes. Diabetes Res Clin Pract 2014; 105(1): 88-95.
36. Stein C, Kramer C, Zinman B, Choi H, Opsteen C, Retnakaran R. Clinical predictors and time course of the improvement in beta-cell function with short-term intensive insulin therapy in patients with type 2 diabetes. Diabet Med 2014, in press
37. Retnakaran R, Qi Y, Opsteen C, Vivero E, Zinman B. Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral anti-diabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab 2010; 12: 909-915.
38. Opsteen C, Qi Y, Zinman B, Retnakaran R. Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. J Eval Clin Pract 2012; 18: 256-261.
39. Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: The LIBRA trial. Diabetes Care 2014, in press {epub ahead of print Sept 23, 2014}
40. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014, in press {epub ahead of print Sept 12, 2014}